News

CRSwNP is a chronic disease of the upper airway, driven in part by type 2 inflammation, that obstructs the sinuses and nasal passages.
The National Medical Products Administration (NMPA) approved an investigational new drug (IND) application for WIN378 to ...
Using data from this trial, Laura Walrave, PhD, MS, BPharm, global medical director of CRSwNP at GSK, and colleagues evaluated 407 patients with at least one previous sinus surgery for CRSwNP to ...
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal ...
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
The monoclonal antibody against thymic stromal lymphopoietin (TSLP) improved total nasal-polyp score by a mean -2.07 points (95% CI −2.39 to −1.74) more than placebo on a 0-4 point scale at 52 ...